title: FGFR-TACC approaches the first turn in the race for targetable GBM mutations.
authors.affiliation: Department of Neurosurgery, Memorial Sloan-Kettering Cancer Center, New York, USA.
authors.forename: Cameron
authors.initials: C
authors.lastname: Brennan
mesh_terms: D001932:Brain Neoplasms; D005909:Glioblastoma; D006801:Humans; D009154:Mutation